Fig. 3From: Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinomaMean and 95% CI over time for participants randomised to DCF alone VS DCF+ RTBack to article page